

# Responding to the challenge of MERS-CoV: development and testing of interventions to reduce risk among Bedouin populations in Southern Jordan

<b>Submission date</b> 18/09/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 28/11/2024	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 28/11/2024	<b>Condition category</b> Infections and Infestations	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Middle East respiratory syndrome coronavirus (MERS-CoV) represents one of three deadly zoonotic betacoronaviruses (alongside SARS-CoV and SARS-CoV-2) to have emerged this century. Since initial outbreaks of MERS in Jordan and Saudi Arabia in 2012, ongoing clinical cases continue to occur, almost exclusively within the Arabian Peninsula. More than 2500 laboratory-confirmed cases have now been identified, across 27 countries, though over 80% of cases have been within the Kingdom of Saudi Arabia (KSA). The World Health Organization (WHO) has declared MERS-CoV to be a Blueprint Priority Disease for Research and Development posing a public health risk of epidemic potential, with more than a third of all confirmed cases currently resulting in death. Dromedary camels are the reservoir host for MERS-CoV, with seropositive camels first identified in 2013, in Jordan. Infection in camels is largely sub-clinical, or causing mild upper respiratory signs, while infection in humans ranges from being asymptomatic to causing potentially fatal severe acute respiratory disease. Alongside primary (camel-to-human) transmission, secondary (human-to-human) transmission also occurs, with the potential for large-scale outbreaks, particularly in hospital settings.

To date, MERS-CoV control efforts have largely focused on i) improved camel testing and surveillance strategies, ii) improved triage and biosecurity measures within healthcare settings and iii) vaccine development, though with no commercial vaccines, human or camel, currently available. However, while likely viral transmission routes and high-risk camel engagement activities have now been identified, the potential role of targeted behavioural interventions, aimed at mitigating MERS-CoV exposure among camel-owning communities, has largely been ignored. The aims of this pilot trial are therefore to i) assess the feasibility and effectiveness of employing behavioural interventions in the control of MERS-CoV, and ii) assess potential ability to scale up for wider evaluation in future trials.

### Who can participate?

The study will be conducted among camel-owning households in southern Jordan – a 40,000 km<sup>2</sup> desert area beside the KSA border. Households will be randomly selected from lists

provided by the Ministry of Agriculture (MoA), and all household members present at the time of the visit will be invited to receive the intervention, except for young children (under 5 years old) and individuals without the capacity to provide informed consent. Household membership will be defined as either i) self-identifying as a household member and sleeping in the household the previous night, or ii) being a household employee.

What does the study involve?

Following a baseline survey of serological status and self-reported practices the planned behavioural interventions have been grouped into 'packages' that address distinct viral transmission pathways and non-communicable disease predisposing to MERS-CoV infection. These packages are as follows:

Package 1. The provision of information regarding the use of face coverings (particularly the traditional 'kaffiyeh') when working with camels, particularly young animals; refraining from kissing camels, particularly young animals; reducing close-quarter exposure to camel crowding (by filling feed and water troughs before allowing camels access); and hand washing after engaging with camels

Package 2. The provision of information regarding improved hand hygiene practices within the home (washing over five times per day with soap)

Package 3. The provision of information regarding the prevention and control of hypertension and diabetes, in accordance with WHO guidelines, in particular regarding smoking, dietary salt intake, dietary sugar intake and physical activity.

Package 4. The provision of information regarding minimizing camel crowding during feeding and watering times through the provision of additional troughs (facilitated by the gifting of one additional trough per five camels in the herd), and closed herd management practices, including quarantining camels (for 3 weeks) entering or re-entering the herd – particularly when used for breeding purposes.

A follow-up telephone call (to the household head) and one follow-up visit to the household home will be conducted 2 and 4 months (respectively) after the initial intervention visits, with the follow-up household visit also used for assessment of outcomes. All visits and telephone calls will be conducted by trained members of an intervention team and will include respected members of the local communities. Households within the control group will also receive the same intervention package as the intervention group, including follow-up visits, after the assessment of intervention uptake among the intervention group has been completed.

What are the possible benefits and risks of participating?

Possible benefits of participating include access to training regarding behavioural interventions with the potential to reduce exposure to MERS-CoV (and potentially serious illness), alongside additional training regarding prevention of important co-morbidities (diabetes and hypertension) and improved hygiene interventions (with the potential to reduce infection from a large range of infectious diseases).

Regarding potential risks or harms in participating, as the interventions are in the form of advice regarding potential behavioural changes (though with minor pain from blood sampling), we expect there to be little potential for harm from the study.

Where is the study run from?

The study is being run by the Royal Veterinary College (RVC) and London School of Hygiene and Tropical Medicine (LSHTM), in partnership with local partners Jordan University of Science and Technology (JUST) and Yarmouk University, Jordan.

When is the study starting and how long is it expected to run for?

October 2020 to February 2025

Who is funding the study?  
UK Medical Research Council (MRC), Global Challenges Research Fund

Who is the main contact?  
Prof. Javier Guitian, [jguitian@rvc.ac.uk](mailto:jguitian@rvc.ac.uk)

**Study website**  
<https://gtr.ukri.org/projects?ref=MR%2FT02996X%2F1>

## Contact information

**Type(s)**  
Public, Scientific, Principal Investigator

**Contact name**  
Prof Javier Guitian

**ORCID ID**  
<http://orcid.org/0000-0003-0799-0476>

**Contact details**  
Royal College Street  
London  
United Kingdom  
NW1 0TU  
+44 (0)20 7468 5000  
[JGuitian@RVC.AC.UK](mailto:JGuitian@RVC.AC.UK)

**Type(s)**  
Public, Scientific

**Contact name**  
Prof Punam Mangtani

**ORCID ID**  
<http://orcid.org/0000-0001-7074-2999>

**Contact details**  
Keppel Street  
London  
United Kingdom  
WC1E 7HT  
+44 (0)20 7636 8636  
[Punam.Mangtani@lshtm.ac.uk](mailto:Punam.Mangtani@lshtm.ac.uk)

**Type(s)**  
Scientific

**Contact name**  
Dr Peter Holloway

**ORCID ID**

<http://orcid.org/0000-0001-6648-9724>

**Contact details**

Royal College Street  
London  
United Kingdom  
NW1 0TU  
+44 (0)20 7468 5000  
pholloway3@rvc.ac.uk

## Additional identifiers

**EudraCT/CTIS number**

Nil known

**IRAS number****ClinicalTrials.gov number**

Nil known

**Secondary identifying numbers**

MR/T02996X/1

## Study information

**Scientific Title**

Effects of a behavioural intervention to reduce MERS-CoV exposure among camel-owning households in southern Jordan: a randomised controlled study

**Acronym**

MERSJORCT

**Study objectives**

Targeted behavioural interventions reduce the risk of MERS-CoV exposure among high-risk camel-owning communities

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

1. Approved 01/04/2022, Observational / Interventions Research Ethics Committee, London School of Hygiene & Tropical Medicine (Keppel Street, London, WC1E 7HT, United Kingdom; +44 (0)20 7636 8636; [ethics@lshtm.ac.uk](mailto:ethics@lshtm.ac.uk)), ref: 26652

2. Approved 18/10/2020, Institutional Review Board, King Abdullah University Hospital, Jordan University of Science and Technology (PO Box 630001, Irbid, 22110, Jordan; +962 (0)27200610; [irb@kauh.jo](mailto:irb@kauh.jo)), ref: 15/136/2020

3. Approved 31/03/2021, Clinical Research Ethical Review Board (CRERB), Royal Veterinary College (Royal College Street, London, NW1 0TU, United Kingdom; +44 (0)20 7468 5300; lwilkinson@rvc.ac.uk), ref: URN 2021 2029-3

### **Study design**

Population-based exploratory blinded parallel individually randomized controlled trial of targeted behavioural interventions

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Community

### **Study type(s)**

Prevention

### **Participant information sheet**

Not available in web format, please use contact details to request a participant information sheet

### **Health condition(s) or problem(s) studied**

Middle East Respiratory Syndrome among camel-owning households in Jordan

### **Interventions**

Block randomisation, block size 6, with even numbers assigned to the intervention group, odd numbers to the control group

#### **Primary interventions:**

Package 1. Zoonotic camel-to-human MERS-CoV transmission. Intervention includes the provision of information regarding:

1. The use of face coverings (particularly the traditional 'kaffiyeh') when working with camels, particularly young animals
2. Refraining from kissing camels, particularly young animals
3. Reducing close-quarter exposure to camel crowding (by filling feed and water troughs prior to allowing camels access)
4. Hand washing after engaging with camels

#### **Supporting interventions:**

Package 2. Secondary human-to-human transmission. Intervention includes the provision of information regarding:

1. Improved hand hygiene practices within the home (washing >5 times per day, with soap)

Package 3. Predisposing comorbidities. Interventions include the provision of information regarding the prevention and control of hypertension and diabetes, in accordance with WHO

guidelines, in particular regarding:

- 3.1. Smoking
- 3.2. Dietary salt intake
- 3.3. Dietary sugar intake
- 3.4. Physical activity

Package 4. Camel-to-camel transmission. Intervention includes the provision of information regarding:

- 4.1. Minimizing camel crowding during feeding and watering times through the provision of additional troughs (facilitated by the gifting of one additional trough per five camels in the herd)
- 4.2. Closed herd management practices, including quarantining camels (for 3 weeks) entering or re-entering the herd – particularly when used for breeding purposes

The control group will receive the same intervention package as the intervention group, after any potential impact of the intervention has been assessed among the study population (by means of self-reported behaviours, observation of behaviours, and serological sampling and laboratory testing by means of MERS-CoV IgG ELISA).

The initial deployment of behavioural interventions among randomly selected households is between September and December 2023, with a telephone call follow-up (to the household head) and follow-up visit conducted approximately 2 months and 4 months after the initial visits, respectively) to reinforce behaviour in the intervention arm.

## **Intervention Type**

Behavioural

## **Primary outcome measure**

Self-reported and observed behaviours from intervention package 1 (i.e., face-covering when working with camels, avoiding kissing camels, filling troughs before allowing camels access and washing hands after working with camels), quantified as binary outcomes, measured 6 months after delivery if the intervention package

## **Secondary outcome measures**

- 1. Self-reported behaviours quantified as binary outcomes from intervention packages 2 – 4, measured 6 months after delivery if the intervention package
- 2. Qualitative data regarding intervention uptake, resulting from thematic and discourse analysis of semi-structured interviews, measured 6 months after delivery if the intervention package
- 3. Serological status on in-house MERS-CoV Spike protein (S1) IgG ELISA, measured 6 months after delivery if the intervention package

## **Overall study start date**

18/10/2020

## **Completion date**

28/02/2025

# **Eligibility**

## **Key inclusion criteria**

Member of a randomly selected camel-owning household (from Ministry of Agriculture lists) in southern Jordan (Ma'an and Aqaba governorates)

**Participant type(s)**

Population

**Age group**

Mixed

**Lower age limit**

5 Years

**Upper age limit**

100 Years

**Sex**

Both

**Target number of participants**

1200

**Total final enrolment**

1200

**Key exclusion criteria**

1. Children younger than 5 years
2. Individuals without the capacity to provide informed consent

**Date of first enrolment**

30/09/2022

**Date of final enrolment**

25/05/2024

**Locations****Countries of recruitment**

Jordan

**Study participating centre**

Ministry of Agriculture, Jordan

39 Al Abdullah Street

Amman

Jordan

11181

**Sponsor information**

**Organisation**

Royal Veterinary College

**Sponsor details**

4 Royal College Street

London

England

United Kingdom

NW1 0TU

+44 (0)1707 666333

vpresearchinnovation@rvc.ac.uk

**Sponsor type**

University/education

**Website**

<http://www.rvc.ac.uk/>

**ROR**

<https://ror.org/01wka8n18>

**Funder(s)****Funder type**

Government

**Funder Name**

Medical Research Council

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Results and Publications****Publication and dissemination plan**

Planned publication in a peer-reviewed journal



**Intention to publish date**

01/01/2025

**Individual participant data (IPD) sharing plan**

The datasets generated and analysed during the current study will be available on request from the corresponding author Dr Peter Holloway (pholloway3@rvc.ac.uk)

**IPD sharing plan summary**

Stored in non-publicly available repository, Available on request